Cantor Fitzgerald’s OnKure Therapeutics OKUR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$273K Hold
100,014
– – ﹤0.01% 563
2026
Q2
$456K Buy
100,014
+114
+0.1% +$489 ﹤0.01% 289
2026
Q1
$414K Sell
99,900
-345,178
-78% -$1.07M 0.01% 227
2025
Q4
$1.29M Sell
445,078
-46,785
-10% -$140K 0.02% 149
2025
Q3
$1.35M Sell
491,863
-177,676
-27% -$440K 0.01% 189
2025
Q2
$1.6M Buy
669,539
+538,839
+412% +$1.41M 0.03% 123
2025
Q1
$562K Buy
130,700
+95,000
+266% +$534K 0.01% 144
2024
Q4
$294K Buy
+35,700
New +$540K 0.01% 150

Other funds holding OKUR

Cantor Fitzgerald's OKUR Position: Q3 2026 in Review

Cantor Fitzgerald held its OnKure Therapeutics (OKUR) position steady in Q3 2026 at 100,014 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #563.

Cantor Fitzgerald first reported a position in OKUR in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.6M in Q2 2025. 81 funds tracked by Wall St. Rank hold OKUR as of Q3 2026.

  • Cantor Fitzgerald held 100,014 shares of OnKure Therapeutics worth $273K as of Q3 2026.
  • Cantor Fitzgerald left its OnKure Therapeutics share count unchanged in Q3 2026.
  • OnKure Therapeutics made up ﹤0.01% of Cantor Fitzgerald's portfolio in Q3 2026, its #563 holding.
  • Cantor Fitzgerald first reported a position in OnKure Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • Cantor Fitzgerald's OnKure Therapeutics position peaked at $1.6M in Q2 2025.
  • 81 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q3 2026.

Based on Cantor Fitzgerald's 13F filing for Q3 2026, filed 16 Nov 2026.